On August 1, 2024, Passage Bio shared they entered into a new agreement with GEMMA Biotherapeutics for the out-licensing of three pediatric gene therapy programs. Through this transaction, Passage Bio has granted GEMMA Biotherapeutics the rights for the development and commercialization of PBGM01 for GM1 gangliosidosis, PBKR03 for Krabbe disease, and PBML04 for metachromatic leukodystrophy.
GEMMA Biotherapeutics, a newly formed company co-founded by Dr. James Wilson, is focused on developing treatments for rare diseases. Dr. James Wilson and his team are dedicated to advancing these promising therapies for underserved patient communities and are committed to share additional updates on the gene therapy clinical programs as they become available.
Read full article here